The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

Financial writer bullish on Synopsys, citing leadership in EDA software, strong financial performance, potential upside, and ...

Synopsys, Inc. (NASDAQ:SNPS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Ratings reports. One ...

Synopsys (SNPS) closed the latest trading day at $525.48, indicating a -0.17% change from the previous session's end. The stock exceeded the S&P 500, which registered a loss of 0.51% for the day. On ...

A new study finds differences in spending on long-term services and supports (LTSS) between people with dual eligibility for ...

Synopsys Inc. closed 16.37% short of its 52-week high of $629.38, which the company reached on February 22nd.

SG Americas Securities LLC lessened its holdings in Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 97.9% during the fourth ...

Synopsys Inc. closed 18.54% short of its 52-week high of $629.38, which the company achieved on February 22nd.

Researchers have identified two microRNA that may predict which individuals with cancer are at elevated risk for ...

There has been some incredible research into the role this DNA plays in modern human neurodevelopment, so here's an overview ...